CJC-1295 (with DAC): Dosage, Benefits & Research Guide
Also known as: CJC-1295 DAC, GRF 1-29 + Drug Affinity Complex
What is CJC-1295 (with DAC)?
CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analogue conjugated with a maleimidopropionic acid (MPA) linker that binds covalently to serum albumin after injection. This albumin conjugation dramatically extends the peptide's half-life from approximately 30 minutes to 6-8 days, enabling sustained elevation of growth hormone levels from a single administration. The mechanism involves the same GHRH receptor activation as the non-DAC version, but the prolonged pharmacokinetic profile produces continuous rather than pulsatile GH stimulation. In a pivotal pharmacokinetic study, Teichman et al. (Journal of Clinical Endocrinology and Metabolism, 2006) demonstrated that a single 60 mcg/kg subcutaneous dose of CJC-1295 with DAC produced sustained GH elevation for 6-14 days and elevated IGF-1 levels for 9-11 days in healthy adult subjects, with a 1.5 to 2-fold increase in mean GH concentrations. This sustained profile is both an advantage and a consideration: while it reduces dosing frequency, the continuous GH elevation does not replicate the natural pulsatile pattern of endogenous GH secretion. Compared to CJC-1295 without DAC, the DAC version is suited for research protocols requiring prolonged GH axis stimulation, while the non-DAC form better models physiological pulse dynamics. Research also suggests potential applications in lean mass preservation, bone mineral density, and sleep quality improvement through sustained GH pathway activation. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. This compound is studied by endocrinology research programs, pharmacokinetics laboratories, and institutions investigating sustained-release peptide delivery strategies.
CJC-1295 (with DAC) Research Applications
In published and preclinical research, CJC-1295 (with DAC) has been studied across the following areas:
- Sustained GH secretion studies
- Lean mass and fat metabolism
- Bone health research
- Sleep regulation through GH pathways
CJC-1295 (with DAC) in Research: Reconstitution & Study Concentrations
The DAC (Drug Affinity Complex) variant of CJC-1295 incorporates a maleimido group that binds covalently to serum albumin, extending half-life from minutes to several days. It is studied for sustained GH/IGF-1 elevation profiles. Reconstitute with bacteriostatic water for laboratory use only.
Worked example: a 5mg vial reconstituted with 2 mL of bacteriostatic water yields 2.50 mg/mL.
Open the reconstitution calculatorHow CJC-1295 (with DAC) Compares
Researchers frequently evaluate CJC-1295 (with DAC) alongside related compounds:
- CJC-1295 (with DAC) vs CJC-1295 (no DAC) — short-acting variant